Oxford Biomedica PLC

Board/Management Information • Jun 4, 2018

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2609Q

Oxford Biomedica PLC

04 June 2018

Directorate Change

London, UK - 4 June 2018: Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE:OXB), a leading gene and cell therapy group, today announces, as previously stated at the Group's Preliminary Results for the year ended 31 December 2017 on 15 March 2018, that Peter Nolan will retire from his role as Chief Business Officer and Board member on 1 July 2018.

John Dawson, CEO of Oxford BioMedica, said: "Peter will retire from his role as Chief Business Officer having worked with the Group for more than twenty years.  On behalf of the Board and management team, I would like to thank Peter for his services to Oxford BioMedica since 1996 - a time during which his contribution to the Group has been significant. I am pleased to say that he will continue to be a Consultant to the Group and we wish him well in his retirement."

- Ends -

For further information, please contact:

Oxford BioMedica plc:                                                                Tel: +44 (0)1865 783 000

John Dawson, Chief Executive Officer

Stuart Paynter, Chief Financial Officer

Financial PR Enquiries:                                                             Tel: +44 (0)20 3709 5700

Consilium Strategic Communications

Mary-Jane Elliott / Matthew Neal /

Philippa Gardner / Laura Thornton

Peel Hunt (Joint Corporate Broker):                                              Tel: +44 (0)20 7418 8900

James Steel / Christopher Golden

WG Partners (Joint Corporate Broker):                                         Tel: +44 (0)20 3705 9321

David Wilson / Claes Sprang

Notes for editors

About Oxford BioMedica

Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the "Group") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Bioverativ, Sanofi, GSK, Orchard Therapeutics, GC LabCell and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 320 people. Further information is available at www.oxfordbiomedica.co.uk.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAUGUMUQUPRGMC